Plus Therapeutics Inc (PSTV) — Titan Protect Analysis

PSTV

Plus Therapeutics Inc

Healthcare · ·

$5.41

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$36M

Total market value of the company

Trailing P/E

0.24

Very cheap relative to earnings

Forward P/E

-2.22

Based on estimated future earnings — lower means cheaper

Rev Growth

-3.2%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$37.50

+593% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat va

https://plustherapeutics.com

Country: United States Employees: 28 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.395

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0278

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.729

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-69.5%

Historical annualised return based on price data

Max Drawdown

-95.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.40

Moves slightly more than the broader market

52W High

$23.50

77% below the year high

52W Low

$2.90

87% above the year low

Avg Volume

310,194

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$21.56

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

20.55

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-60.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-420.0%

Profit from core operations before interest and tax

Free Cash Flow

$-13,597,750

Negative — the business is spending more than it generates

Revenue (TTM)

$5M

Total revenue over the last 12 months

Net Income

$-22,386,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$65.00

Target Median

$37.50

Target Low

$12.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go